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A B S T R A C T   
There is growing interest in the radiotherapy community in the application of FLASH radiotherapy, wherein the 
dose is delivered to the entire treatment volume in less than a second. Early pre-clinical evidence suggests that 
these extremely high dose rates provide significant sparing of healthy tissue compared to conventional radio-
therapy without reducing the damage to cancerous cells. This interest has been reflected in the proton therapy 
community, with early tests indicating that the FLASH effect is also present with high dose rate proton irra-
diation. 
In order to deliver clinically relevant doses at FLASH dose rates significant technical hurdles must be over-
come in the accelerator technology before FLASH proton therapy can be realised. Of these challenges, increasing 
the average current from the present clinical range of 1–10 nA to in excess of 100 nA is at least feasible with 
existing technology, while the necessity for rapid energy adjustment on the order of a few milliseconds is much 
more challenging, particularly for synchrotron-based systems. However, the greatest challenge is to implement 
full pencil beam scanning, where scanning speeds 2 orders of magnitude faster than the existing state-of-the-art 
will be necessary, along with similar improvements in the speed and accuracy of associated dosimetry. Hybrid 
systems utilising 3D-printed patient specific range modulators present the most likely route to clinical delivery. 
However, to correctly adapt and develop existing technology to meet the challenges of FLASH, more pre-clinical 
studies are needed to properly establish the beam parameters that are necessary to produce the FLASH effect.   
1. Introduction 
The challenge in radiotherapy has always been to optimise the 
Tumour Control Probability (TCP) over the Normal Tissue Complication 
Probability (NTCP) [1]. The introduction of proton beam therapy al-
lowed a similar conformal dose to be delivered to the treatment volume 
but with a lower dose to the surrounding healthy tissue that improves 
the TCP/NTCP ratio [2]. Recently, a new method of dose delivery has 
shown extremely promising results in the sparing of normal tissue with 
little reduction in tumour control [3]. Termed FLASH radiotherapy, this 
technique involves delivering the same treatment dose but in much 
shorter time intervals — fractions of a second as opposed to minutes — 
and in far fewer fractions (or even a single fraction) and therefore at 
dose rates that are thousands of times higher [4]. First reported in 2014  
[5] and confirmed in multiple subsequent experiments (e.g. [6–10]), in 
several tissue types FLASH has demonstrated that these high dose rates 
do provide a significant improvement in the TCP/NTCP ratio. A recent 
first patient treatment indicates this technique has promise [11]. While 
these experiments were carried out with electrons and X-rays, the si-
milar RBE of protons has also increased interest within the proton 
therapy community [12] and experiments have shown that such effects 
could also be achieved using protons [13]. Coupled with the improved 
dose distribution offered by Proton Beam Therapy (PBT) treatment, the 
suggestion is that further improvements can be realised when deli-
vering FLASH treatments with protons [14]. The issue, however, with 
present-day clinical PBT systems is that many of the machine char-
acteristics fall short of the requirements needed for FLASH dose de-
livery: a summary is given in Table 1. While experimental setups for 
delivering FLASH dose rates with existing clinical systems have been 
realised [15–17], these have so far been limited to small volumes. This 
is not unexpected since the requirements for conventional PBT dose rate 
are several orders of magnitude below that required for FLASH. 
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2. Clinical dose rate requirements 
A common clinical specification for minimum dose rate for con-
ventional proton therapy is to be able to deliver a dose of 2 Gray for a 
single field to a 1 litre volume in 1 minute [31,32]. For a cubic 
× ×10 10 10 cm3 volume that lies from 10–20 cm deep within another 
larger water volume, this corresponds to ×1.9 1011 protons.1 This value 
is important for future discussions since, by scaling up the dose rate 
from conventional to FLASH PBT and assuming the same fractionation 
scheme, one can set a lower limit on the total number of protons and 
the proton rate needed for FLASH delivery. ×1.9 1011 protons is 
equivalent to ∼30 nC: for dose delivery at FLASH rates, wherein all the 
dose is delivered in 100 ms, this corresponds to a beam current of 
300 nA at the patient, or a dose rate of 20 Gy/s. As such, the accelerator 
and beam delivery system must be capable of delivering an average 
current of 300 nA to the patient in order to meet the current clinical 
specification: of the existing medical proton accelerator technologies, 
only isochronous cyclotrons are capable of delivering such a sustained 
current and then only at the highest energies (see Table 1): losses in the 
beam transport between accelerator and patient also reduce the in-
tensity at the patient, particularly at low energies. A volume perhaps 
closer to standard clinical scenarios is one of × ×5 5 5 cm3 ie. a 125 ml 
volume that is an eighth of the standard 1 litre clinical volume: if one 
considers such a volume lying 15–20 cm deep within another larger 
water volume, this requires ×2.8 1010 protons and therefore a charge of 
4 nC or a current of 40 nA for delivery within 100 ms. 
A consensus on the beam parameters that can be considered as 
FLASH has not yet been established: the exact specification is likely to 
be an interdependent combination of dose, dose rate, repetition rate 
and number of pulses [35]. The effects of multiple fields is also not yet 
known, and there remain many open questions as to the cumulative 
effect of FLASH doses delivered either to different regions of one tu-
mour volume, or from different field directions to the same volume. 
However, the commonly accepted definition is for dose rates above 
40 Gy/s [35,36]. Assuming that 40 Gy/s dose rates can be delivered for 
100 ms, this equates to a total dose of 4 Gy or ×3.8 1011 protons for the 
standard 1 litre clinical volume quoted above, equivalent to a 60 nC 
of charge or 600 nA average current, or an average current of 40 nA for 
the smaller 125 ml subvolume. This is the specification for delivered 
beam current used in subsequent calculations. The particular values for 
some example treatment plans, including the ones described above, are 
given later in Table 2. This assumes that the dose averaged dose rate 
(DADR) is the figure of merit [14], wherein the entire dose must be 
delivered at a rate 40 Gy/s and within 100 ms for the entire volume, 
utilising a single field. It may be that FLASH effects can also be achieved 
by delivering at such rates to smaller sub-volumes within a larger 
treatment volume: this would thereby relax the time constraint and 
allow high doses to be delivered in short pulses. It is plausible that the 
figures of merit might be the delivery time and dose rate not to the 
tumour but to healthy tissue: as such, treatment scenarios — particu-
larly with multiple fields — may eventually be realised wherein the 
dose delivery to the entire tumour volume falls below the minimum 
FLASH requirements but the healthy tissue-sparing FLASH effect can 
still be realised. However, for the purposes of the subsequent discussion 
and calculations, a DADR of 40 Gy/s is assumed for a single field plan, 
thereby requiring an average current of 600 nA for the 1 litre volume or 
40 nA for the smaller subvolume; this is the minimum requirement for 
delivering FLASH proton therapy considered here. 
Even for the larger volume, such a dose rate is not very far from the 
currents available using some existing PBT accelerator technologies  
[37,38] — for example, the PSI COMET cyclotron is capable of deli-
vering a sustained extracted current of 800 nA [20,39] — but certain 
improvements would be needed to ensure a clinically safe system, not 
least of which is ensuring safe delivery of a specified dose to a treatment 
volume (see Section 4.2). Whilst modern isochronous cyclotrons are 
capable of delivering large currents, one important limitation they have 
is that lossy energy degraders must be used to select treatment energies 
lower than the fixed extraction energy of the cyclotron. Beam losses due 
to the degrader at the lowest delivered energies around 70 MeV can 
exceed 99%, which precludes the use of certain beam delivery mod-
alities for FLASH unless increased beam currents are available: the 
various beam delivery options are discussed in Sections 3–5. 
The above discussion assumes that one is still mimicking the frac-
tionation regime of current clinical treatment with a single field, whilst 
treating at FLASH dose rates: in a normal fractionated treatment the 
total dose (say, 60 Gy) is spread over 30 or so fractions of 2 Gy each, 
with multiple fields within each fraction. If hypofractionation is used 
(wherein the total dose is delivered in only a few fractions or even in a 
single fraction), that implies a dose rate of 600 Gy/s. This sets a much 
more challenging accelerator requirement of ×6 1012 protons or 1 µC 
of charge for the 1 litre volume. Delivering this in 100 ms requires an 
average current of 10 µA, well above the capabilities of any existing 
clinical proton accelerator. 
The discussion that follows assumes the minimum FLASH dose rate 
quoted in the literature of 40 Gy/s and therefore a total of 
×3.8 1011 protons or 60 nC of charge at an average current of 600 nA, 
delivered in 100 ms to a 1 litre volume: where appropriate, comparisons 
Table 1 
Parameters for clinical accelerator systems for which information is available; a representative subset of recent systems is shown. Note that the maximum number of 
particles is given per bunch for the isochronous cyclotron (wherein the beam is a continuous stream of bunches with a spacing equivalent to the acceleration 
frequency) but per pulse for all other technologies; and that the maximum accelerating field is given for the linear accelerator rather than the magnetic field. Also 
note that while the extracted beam from a synchrotron is continuous, the injection/acceleration cycle means the effective duty factor is about 50%. See Section 7 for 
more details.         
Accelerator Type Isochronous Cyclotron Synchrocyclotron Synchrotron Linear Accelerator  
Vendor IBA Varian IBA Mevion Hitachi AVO 
System C230 PROBEAM S2C2 S250 ProBeam LIGHT 
Maximum Energy (MeV) 230 250 250 250 250 250 
Minimum Energy (MeV) 70 70 70 70 70 37.5 
Peak Current(µA) 0.3 0.8 18 7 ×4.8 10 3 40
Max Ave. Current (nA) 300 800 130 32 4.8 32 
Accel. Frequency (MHz) 106.1 72.8 87.6–63.2 133–90 1.3–10 3,000 
Repetition rate CW CW 1 kHz 500–750 Hz CW 200 Hz 
Treatment Pulse Length >400 µs >400 µs 7 µs 6 µs 0.5–5 s 4 µs 
Bunch Length 2 ns 2 ns 2 ns 2 ns 25–200 ns 0.5 ns 
Max Part. per Bunch/Pulse 100,000 70,000 ×8 108 ×4 108 ×1.5 1011 1010
Electric/Central Field 1.7 T 2.4 T 5.75 T 9 T 1.7 T 25 MV/m 
References [18,19] [20,21] [22] [23–25] [26–28] [29,30] 
1 Treatment planning calculation carried out by Christian Gräff, GSI, using the 
TRiP98 treatment planning software [33,34]. 
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are also given to the smaller 125 ml subvolume. In order to deliver 
hypofractionated treatment rates any of the quoted times need to be 
reduced by a factor of 15. In addition, to simplify the discussion, only 
single field delivery is assumed. 
3. FLASH proton delivery: double-scattering systems 
The simplest way to meet the current requirement discussed above 
would be with the more traditional double-scattering arrangement: 
experimental versions of such systems have already been realised [17]. 
In utilising patient-specific range shifters and collimators and delivering 
a constant current, the “active” part of the beamline is reduced only to 
the range modulator wheel or ridge filter that is used to produce the 
necessary energy/range variation for the given treatment volume. In 
comparison to existing clinical PBT systems, a double-scattering FLASH 
beamline must meet the following additional requirements:  
1. The accelerator must be able to deliver a suitably high continuous 
current such that FLASH dose rates can still be achieved despite the 
transmission losses of the double scattering system, which can be 
more than 50%.  
2. The accelerator beamline must be able to withstand this higher peak 
current. In particular, if intercepting diagnostics are permanently 
inserted into the beamline, the thousandfold increase in in-
stantaneous current must be tolerable.  
3. Extra beam losses at collimators, beam diagnostics and range- 
shifting materials at the patient will create activation and neutrons: 
these must be monitored and minimised.  
4. The dose-monitoring and beam-interrupting systems must be able to 
respond quickly enough to shut off the delivered beam once the 
required dose has been delivered — or in case an error is detected — 
to ensure that the patient is not overdosed.  
5. The mechanical system used to produce the variation in range — 
such as a range modulator wheel — must adjust quickly enough that 
many passes over the treatment volume are possible within the 
FLASH delivery time to ensure the volumetric dose deposition is not 
susceptible to temporal changes in the proton rate. 
6. The on-line data analysis of the dose monitoring must remain syn-
chronous to the modulated beam energy, in order to obtain the 
proper dose readout. 
Transmission losses through a double-scattering system are usually 
in the range 50–80%; with this reduction, the existing PSI COMET cy-
clotron would be able to deliver a continuous current anywhere from 
160–400 nA at the patient, capable of meeting the maximum current 
requirement for the 125 ml volume but falling short of the clinical re-
quirements for the 1 litre volume set out earlier in Section 2. As such, 
more efficient scattering systems in combination with a larger proton 
source current will be required to meet the 40 Gy/s FLASH rate with a 
double-scattering system: improvements in transmission are, however, 
likely to be modest. 
Intercepting diagnostics do exist that can withstand much higher 
currents than those that will be encountered in FLASH treatments: in 
addition, it is not an absolute necessity to utilise permanently- 
intercepting diagnostics, given the large range of non-intercepting di-
agnostics already in use in modern accelerators [40]. Together with 
Points 1 and 5 above, this weighs against the use of accelerator tech-
nologies that give pulsed beam delivery output, such as synchro-cy-
clotrons and linacs (see Sections 8 and 9). In particular, as with existing 
facilities a FLASH double-scattered system clearly favours the use of 
isochronous cyclotrons: a bunch acceleration frequency in excess of 
10 MHz gives an effectively continuous beam, and along with the sta-
bility of the extracted current ensures no interplay between any range 
modulator and the beam bunch structure. Pulsed beams may be pos-
sible if the time structures in which beam delivery systems are working 
do not interfere with the time structure of the beam pulses, for example 
by using a ridge filter instead of a modulation wheel. Synchrotrons are 
less attractive because of the increase in cost and complexity needed to 
meet the higher dose rate specification (see Section 7). 
Being able to actively monitor the delivered dose is probably the 
most challenging area in realising such a clinical system. The dose 
monitor must be able to accurately measure peak dose rates thousands 
of times higher than existing clinical systems and react with equal speed 
in order to shut off the beam once the correct dose has been delivered. 
In addition, this dose monitor will need to be able to communicate with 
the remainder of the accelerator control system with sufficient speed to 
shut off the beam rapidly enough to prevent significant unwanted dose 
being delivered. Further discussions on FLASH dosimetry requirements 
are given in Section 4.2. 
Whilst passive scattering offers some advantages over beam scan-
ning for high dose-rate delivery, the limitations of a passive-scattering 
system are still present:  
1. Collimators and range shifters have to be manufactured for each 
patient and for each field. A multi-leaf collimator (MLC) would 
provide an alternative, but no clinical systems currently exist. Range 
shifters or degraders could be replaced by ridge or pin filters, pro-
vided the following beam transport system has a sufficiently large 
energy acceptance: more detail is given in Section 5.2.  
2. The dose is not as conformal to the treatment volume since the 
proximal edge of the dose delivery volume is a shallower replica of 
the distal edge, and not of the proximal edge of the treatment vo-
lume (the depth range is approximately constant across the treated 
volume).  
3. There is a significant increase in neutron dose to the patient as a 
result of the extra material that intercepts the beam. 
It is for these reasons that newly-installed PBT systems pre-
dominantly offer spot scanning. 
4. FLASH proton delivery: spot scanning 
Whilst mitigating the shortcomings of passively scattered beamlines 
outlined above, delivering FLASH PBT with modern spot-scanning 
systems is considerably more challenging. While the average beam 
current requirement given above for double-scattered systems still 
holds, for spot-scanning systems the actual delivered current will be 
significantly higher since one must account for the dead time between 
Table 2 
Comparison of three example treatment plans for 4 Gy delivery to a cubic water volume in a single fraction using a single field. For the 1 litre Gräff plan, all but the 4 
proximal layers have more than 2,500 spots per layer.           
Plan Name Dimensions Total Protons Layers Total Spots Spots/Layer Spot Spacing      
Min Max Ave   
Gräff 1 litre × ×10 10 10 cm3 ×3.8 1011 34 96,222 595 3,425 2,830 2 mm 
Gräff 125 ml × ×5 5 5 cm3 ×5.5 1010 17 10,622 622 625 625 2 mm 
van de Water × ×10 10 10 cm3 ×3.3 1011 16 1,912 7 310 120 1–102 mm 
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spots, for switching energy layers, and for the variation of beam current 
required in each layer/spot to create a uniform dose distribution. In 
addition, rather than having a “static” magnetic beamline that does not 
have to adjust whilst the protons are delivered to the patient, with spot- 
scanning the beamline is “active”: steering magnets within the nozzle 
must direct the pencil beam to the desired spot within the treatment 
volume and every magnet within the entire beamline must also adjust 
to match the beam energy for a given energy layer. 
In the future, rapid energy variation will demand beam delivery 
systems with large energy acceptance; rather than adjust the magnet 
settings for each energy layer, the beam dispersion is limited by a 
suitable beam-optical arrangement and sufficient aperture within the 
magnets and vacuum system provided to obtain a large energy accep-
tance. There are broadly two types of design: smaller-acceptance de-
signs that have an energy acceptance sufficient for a single treatment 
depth range, in which the gantry optics are often composed of several 
conventional magnetic achromats [41–43]; and large-acceptance de-
signs which aim to allow any energy from an accelerator source (say, 
from 70 MeV to 250 MeV) with no magnetic adjustment at all. For the 
latter case, FFAG (fixed-field, alternating gradient) optics, or achro-
matic multipole-based bending systems, are often proposed and since 
the magnets are fixed one may use more compact designs that utilise 
either permanent magnets or superconducting magnets to limit com-
plexity and mass [44–47]. 
In smaller-acceptance systems there is the option of having a range- 
shifting device just before the patient, since then the magnet currents 
do not have to switch with beam energy. In addition to this, the time for 
a given magnet to adjust and stabilise must reduce with the time taken 
to deliver the beam ie. by a factor of a thousand compared to present- 
day treatment rates. In this respect the development of continuous 
scanning is of interest [14], since this will eliminate a large fraction of 
the dead time between spots. Again, the dose monitoring requirements 
are stringent: however, unlike a passively-scattered system, one is no 
longer monitoring the current of the entire beam but must monitor spot 
by spot. It should be noted that these requirements are common across 
all clinical spot-scanning systems, irrespective of the accelerator tech-
nology that drives them. 
Clearly, for a spot-scanning system the total number of spots and 
energy layers is critical in establishing a baseline for the overall speed 
of the system. Due to the open questions about how FLASH treatment 
might be delivered, delivery of a single 4 Gy fraction applied using a 
single field is assumed; multiple-field treatments are expected to reflect 
the issues seen in single-field delivery. In order to provide greater spot 
and layer switching time, an optimised treatment plan for the 1 litre 
volume was recalculated using the method described in [14]. This spot- 
reduced “van de Water” plan reduced the number of energy layers to 
16, with a maximum number of spots in any layer of 310,2 partly 
through variations in the beam spot size from 2–20 mm. A longitudinal 
slice through the resulting dose distribution of this spot-reduced plan is 
shown in Fig. 1. The total number of protons was reduced slightly from 
3.8 to ×3.3 1011 when compared to the “Gräff” plan introduced in 
Section 2, thereby reducing the average current for a 40 Gy/s dose rate 
to a 1 litre volume to 520 nA. The differences between the three cal-
culated treatment plans are summarised in Table 2. 
In combination with a large energy acceptance, a very fast change of 
energy could be faster than the lateral shift of the pencil beam. This can 
be achieved by using by a rapidly-adjusting degrader or by using a 
ridge- or pin-filter (see Section 5.2). As will be clear from the discus-
sions on lateral scanning speed in the next sections, use of such a filter 
would enable other sequences in the dose delivery process, such as for 
example column painting instead of layer painting. 
4.1. Magnet switching 
In existing clinical Treatment Planning Systems (TPS) the energy 
layer spacing is on the order of 3 mm: for the standard 1 litre volume 
this corresponds to 30 energy layers. To deliver the full volume at 
FLASH rates the accelerator system must therefore deliver a single 
layer, then adjust the energy and be ready to deliver the subsequent 
layer in 3 ms. Using the spot-reduced treatment plan described above, 
since the number of energy layers is reduced to 16 this time increases to 
6 ms: this is also true for the 17-layer 125 ml volume. This time will 
vary slightly, depending upon whether the system is limited by max-
imum beam current or magnet switching time: since somewhere around 
10 times more protons need to be delivered for distal than proximal 
layers, the distal layer can either take longer to deliver than the prox-
imal layer in the former case or be delivered at a higher current in the 
latter. The available time budget can be subdivided into 2 parts:  
1. Delivery of a single energy layer;  
2. Adjustment of energy between layers. 
Given that the total time budget per layer is 6 ms, this implies that 
each of these can take no more than 3 ms. One can envisage that, 
whilst the accelerator is adjusting the beam energy for the next layer, 
the beamline is also preparing for the delivery of this new energy. As 
such, for a system using conventional beamline optics, each of the 
beamline magnets — quadrupoles, dipoles etc. — must be able to adjust 
to and stabilise at the correct field settings in around a millisecond. This 
is not beyond the realms of existing technology given that, for example, 
the ISIS Rapid Cycling Synchrotron (RCS) ramps up in energy at a rate 
of 70 MeV/ms [48,49]. However, the difference for a clinical beam-
line is that the magnets must adjust and then stabilise rather than cy-
cling continuously over a range of fields. An alternative would be to use 
a beamline with a suitably wide energy acceptance such that all mag-
netic fields vary at the same speed during beam delivery, or such that 
the magnets could be set to accept the complete range of energies for a 
given treatment plan. Such designs have already been investigated for 
compact, large energy acceptance gantries [50,47] but prototype clin-
ical systems have not yet been realised. 
For a scanning system the most severe requirements are those 
placed on the nozzle scanning magnets. For the aforementioned 1 litre 
Fig. 1. Longitudinal dose distribution (in z) for the central slice of the spot- 
reduced “van de Water” treatment plan [14]; beam enters from above. The 
colours indicate the fraction of the maximum dose within the plan. Note the 
dose uniformity within the treatment volume despite the reduction in number 
of spots by 2 orders of magnitude. 
2 Spot reduction treatment planning calculation carried out by Steven van de 
Water, PSI [14]. 
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water volume, a typical layer contains 2,500 spots in a ×50 50 grid 
pattern; for the × ×5 5 5 cm3 125 ml volume all bar the proximal layer 
contain 625 spots in a ×25 25 grid pattern; for the spot reduction plan, 
each layer contains at most 310 spots: the spot array is, however, dis-
tinctly non-uniform, with gaps between spots adjacent anywhere be-
tween 1 and 102 mm. As such, the calculations below are based upon 
the common minimum spacing of all plans of 2 mm per spot. For the 
1 litre volume, if each layer has to be delivered in 3 ms, that places a 
limit of 1.2 µs for each spot to be delivered and the nozzle magnets to 
adjust and steer the beam on to the next spot. For the 125 ml volume 
this time extends to 5 µs. Assuming a similar time budget for the energy 
layer adjustment, with a 50/50 split between steering and beam de-
livery, this requires both the horizontal and vertical scanning magnet to 
adjust and settle in 600 ns, or 2.5 µs for the 125 ml volume. This 
assumes that the scanning system utilises a step-and-shoot approach 
wherein the beam is switched off entirely between spots. With a gap 
between spots of 2 mm, this means a scanning speed of 2 mm/600 ns, 
or 3 m/ms at isocentre for a 1 litre volume or 75 cm/ms for a 125 ml 
volume. By comparison, the fastest scanning speed possible on PSI 
gantry 2 is 2 cm/ms [39]. As such, to meet the provisional FLASH 
specifications requires an increase in scanning speed by 2 orders of 
magnitude. While magnet systems capable of steering at such speeds 
already exist in high-energy physics facilities, realising a cost effective 
clinical system that is able to achieve such a speed, in combination with 
the stepping process, is extremely challenging. 
This requirement can be relaxed slightly if a continuous scanning 
method is used rather than step-and-shoot, meaning that the beam does 
not switch off during a single layer scan but is scanned continuously 
across the energy layer (for a description of this technique, see [51]). 
For a continuous scan of a 1 litre volume, the scanning speed is reduced 
somewhat: the beam must scan a total distance of 510 cm — 50 lines of 
10 cm each, plus the orthogonal 10 cm to move lines — which must be 
covered in 3 ms, giving a scanning speed of 1.7 m/ms, which is half 
the speed requirement of step-and-shoot; for a 125 ml volume this drops 
further to 43 cm/ms. However, using a continuous scan places tighter 
requirements on the stability and monitoring of the delivered dose, 
since the pencil beam moves faster over the volume. Unless beam 
current fluctuations occur on much shorter timescales than that for the 
dose delivery i.e. over nanoseconds, dose errors are more difficult to 
overcome with continuous scanning, particularly if there are systematic 
offsets in the dose delivery. Online monitoring and feedback is also 
more challenging due to the interplay between dose delivery and 
scanning speed. It also means that spot-reduced plans — such as the one 
discussed above — cannot be delivered since the spot reduction process 
necessarily removes certain spots, meaning that the beam must be 
switched off between spots. 
4.2. Dosimetry 
As noted above, for the step-and-shoot method the time budget for 
delivering protons to a given spot is 600 ns in order to ensure delivery 
of the standard 1 litre clinical plans within 100 ms. For existing clinical 
systems with a dose rate of 2 Gy/min, this time is in the range 1–20 ms, 
around four orders of magnitude slower. This places severe constraints 
on the various dosimetry systems that monitor the beam. 
At present, the number of protons delivered to a given spot is 
governed by the dose monitors in the nozzle near the patient. As pro-
tons are delivered, these dose monitors record the amount of deposited 
dose until it has reached the required level, taking account of the delays 
inherent in the dose monitoring instruments (usually ion chambers). At 
this point, the signal is sent to the accelerator to switch off the beam. 
The beam delivery system is then adjusted to prepare for protons to be 
delivered to the next spot and the process continues. In order to achieve 
this, the dose monitors need to have the necessary accuracy to ensure 
the correct dose is delivered within the required tolerance levels: this is 
normally <10%, but for FLASH this is not known yet. They also need to 
be able to respond quickly enough to shut off the beam once the desired 
dose has been reached for a given spot. In addition, should a safety 
interlock occur, the beam must be shut off rapidly enough that the 
patient is not in danger of being overdosed. This means that the dose 
monitors as well as the associated data-acquisition systems have to be 
able to monitor considerably faster than the time for delivering the 
beam to a single spot, so faster than 100 ns. 
At such short times, existing ionisation chambers become com-
pletely redundant: amongst other issues, the drift time of the ions and 
electrons within an ionisation chamber is simply too slow to be able to 
provide continuous sampling of the delivered dose and saturation ef-
fects introduce nonlinearities into the ionisation chamber response 
which are difficult to correct for at extremely high doses [52,53]. As 
such, new dose monitoring techniques will be required. One possibility 
is the use of fast scintillators: plastic scintillators have time constants on 
the order of a few nanoseconds so could provide an alternative. How-
ever, the disadvantage of using scintillators is that the light output is no 
longer a linear function of dose: due to light quenching, the proportion 
of dose converted to light decreases with higher ionisation density, for 
example in the Bragg peak. Unlike ionisation chambers, scintillators 
also “burn out”, wherein the light output decreases over time with in-
creased integral dose. It is likely, therefore, that new technology, such 
as gas scintillation, will be required in order to provide online mon-
itoring of the required dose with a spot-scanning system [54]. 
The alternative would be to fundamentally change the methodology 
behind clinical proton beam delivery. At present, the dose is monitored 
constantly and the amount of protons for each spot “drip-fed” over 
many pulses until the required dose is reached. If the amount of protons 
in each pulse can be regulated to within the 10% tolerance given above, 
it no longer becomes necessary to deliver protons in this way: the 
correct amount of protons for each spot is already known a priori by the 
accelerator. This, however, requires significant improvements in the 
stability of proton delivery from all existing accelerator systems. 
5. FLASH proton delivery: hybrid systems 
A third possibility that falls somewhere between traditional scan-
ning and scattering methods is to employ a combination of both tech-
nologies. There are two possible options:  
1. Use a broad beam of a single energy that covers the entire treatment 
volume. The energy of the broad beam is then varied to cover 
multiple depths. 
2. Use a spot-scanned beam, but employ a range modulator to in-
troduce the required energy spread into the beam, essentially deli-
vering a Spread Out Bragg Peak (SOBP) spot by spot. 
It should be noted that neither of these options would be able to 
utilise the van de Water spot reduction method mentioned above [14], 
since both methods require a contiguous irradiation field. As such, the 
accelerator and beamline requirements for each method are based on 
the proton rates given in Section 2. 
5.1. Hybrid delivery: broad beams 
Option 1 requires a beam that is larger than the given field size and 
is therefore similar to traditional scattering systems. However, in order 
to deliver a conformal dose, the energy of the beam not only needs to be 
varied but the beam size also needs to be adjusted to match the 
transverse size of the tumour at each energy layer. This requires the use 
of a suitable MLC that adjusts the transverse size of the beam to match 
the tumour at the given energy layer. Based on the values given at the 
beginning of Section 4.1, wherein the budget for layer delivery and 
switching is 3 ms, the MLC needs to adjust and settle in 1 ms. This is 
not possible with existing MLC systems used in conventional (photon) 
radiotherapy linacs, and it is difficult to envisage how such a 
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specification might be achieved. It should also be noted that there are 
no MLCs in clinical operation for proton therapy. As with spot-scanning 
systems, this option also requires energy variation at the same speed as 
the MLC variation. 
The advantage, however, is that dose no longer needs to be mea-
sured for an individual spot but instead for an entire layer. This means 
dose can be measured at similar speeds to present spot-scanning sys-
tems, i.e. on the order of 1 ms for total dose delivery. Although the 
maximum dose to be monitored is 2,500 times higher, both the dynamic 
range and the speed of the dose monitors are similar to existing re-
quirements. 
5.2. Hybrid delivery: spot scanning 
In option 2, the opposite approach is chosen: the beam is now 
scanned across the target but an energy variation is introduced such 
that all energy layers are delivered simultaneously [56]. Clearly, in 
order to get accurate scanning, this energy spread must be introduced 
after the scanning magnets in order that the scanned beam reaches the 
correct target volume in the tumour: this is currently achieved with 3D- 
printed range modulators [55]. An example of such a range modulator 
is shown in Fig. 2. The range modulator sits next to the patient and 
consists of a series of vertical pyramid-shaped pins with the same 
transverse dimensions of an individual spot that introduce an energy 
spread into the beam. This energy spread can be customised for each 
spot by tailoring the height of each pin. Experimental facilities have 
been designed that employ this technique [57]. This method has the 
advantage that the energy adjustment from the accelerator — and 
therefore any corresponding magnetic adjustment — is completely re-
moved. As such, so long as the time structure of the beam is suitable, 
any of the available accelerator technologies can deliver the beam. 
Notwithstanding the scanning magnets themselves, the magnetic 
beamline is also completely static during delivery of a single field. 
Compared with a pure spot-scanning system, the required scanning 
speed for a 1 litre volume is significantly reduced: with 2,500 spots 
delivered in 100 ms, the spot dwell time would be 20 µs with 
20 µs to steer the beam between spots. For a 125 ml volume this 
scanning speed reduces further, with both a dwell and steering time of 
80 µs. This is still quite challenging but less so than a pure spot- 
scanning system. 
The disadvantage of a 3D-printed range modulator is that, as with 
the absorbers and collimators needed for conventional double-scattered 
proton therapy, one must be printed for every field that is delivered to 
every patient. In the case of multiple fractions, if the treatment plan 
needs to be adjusted between fractions then new range modulators are 
also needed. In addition, the material needs to be selected carefully to 
prevent significant additional neutron dose to the patient. Finally, 
compared to option 1 the dosimetry requirement becomes considerably 
more challenging, since the dose must be measured at least 40 times 
faster for a 125 ml volume and over 70 times faster for a 1 litre volume, 
but with the same accuracy. 
6. Cyclotrons 
Meeting the challenges and requirements set out in the previous 
sections places new requirements on the accelerator used for producing 
the beam. By far the most common accelerator used for existing clinical 
PBT systems is the cyclotron. The layout of a typical cyclotron-based 
facility is shown in Fig. 3 Experiments by IBA have been publicised in 
which small volumes have received FLASH dose rates using a normal 
conducting clinical cyclotron and scanned-beam delivery [58]. For a 
125 ml volume, a dose rate of 45 Gy/s delivered in 540 ms was 
achieved; for a smaller × ×2 2 2 cm3 volume a rate of 200 Gy/s deliv-
ered in 170 ms was observed [58]. While these experiments do not yet 
meet the dose rate and delivery time for the 1 litre standard defined in 
Section 2, they clearly demonstrate the potential for cyclotrons to de-
liver FLASH proton therapy. 
Since a cyclotron produces a continuous beam of high intensity at a 
fixed energy, a degrader is necessary to produce the necessary variation 
in energy. One method to achieve fast intensity variation is by means of 
beam intercepting systems in the central region of the cyclotron, where 
the beam energy is still low enough to prevent activation and cooling 
problems. Present-day typical maximum extracted beam intensities 
from a proton therapy cyclotron are in the range 100–800 nA. More 
modern ion source designs and central region layouts could perhaps 
increase the extracted current by a factor of ten, thereby meeting the 
continuous current requirement for FLASH (see Section 2). For cyclo-
trons the biggest challenges in delivering FLASH with a cyclotron are 
related to beam energy. Beam energy cannot be modified very rapidly 
in a cyclotron: the beam energy is controlled by a degrader in the beam 
transport system that introduces a variable ionisation loss by varying 
the physical thickness and/or density of inserted degrader material. For 
FLASH systems which require energy variation from the accelerator, the 
degrader should be able to change the beam energy very fast — perhaps 
<0.1 ms/energy step — which is challenging. However, when it is 
mounted at a location where the beam cross section is only a few 
millimetres, such as a beam-optical waist, the design can benefit from 
the small distances to be covered to insert material into or out of the 
beam path. 
A major disadvantage of a degrader is the scattering that accom-
panies the ionisation loss that leads to an increase of the beam emit-
tance and energy spread; this effect becomes very serious at lower en-
ergies. The characteristics of the desired dose distribution at the patient 
determine the trade-off between the emittance and energy spread 
chosen from the exit distribution (by means of an energy selection 
system and collimators) and the obtained current and spot size at the 
patient. For example, at the PSI PROSCAN facility the beam spot size is 
kept reasonably small (less than 10 mm) even at the lowest, most-de-
graded energies, and with an energy spread less than 1%; the con-
sequence at 70 MeV is an overall transmission of only 0.1% [59,60]: 
more than 99% of the beam extracted from the cyclotron is lost, which 
places a lower limit on the energy that (high-energy) cyclotrons can 
deliver with an acceptable intensity. Typical intensity reductions cause 
by a cyclotron ESS are shown in Fig. 4. Improved degrader geometries 
may help somewhat [60,61], but it also suggests the need for dedicated 
lower-energy intense cyclotrons that avoid the need for some of the 
degrader material. Should a single cyclotron be used to cover all the 
clinical energy ranges, and assuming the existing transmission loss of 
99% at low energies, currents approaching 100 µA will need to be ex-
tracted to meet the requirements for the 1 litre volume set out in Section  
2. Such currents are achievable with cyclotrons, but are two orders of 
magnitude above the limits of existing clinical systems. As such, 
adaptation of high current cyclotron designs will be necessary in order 
to realise a clinical FLASH system with full spot scanning. It is likely, 
Fig. 2. Example of a 3D range modulator; top view (a) and a quarter of it, side 
view (b); image taken from [55]. Diameter =d 5 cm, height =h 4.6 cm. 
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therefore, that the first clinical FLASH systems will utilise cyclotrons 
delivering beam via the hybrid systems described in Section 5.2. 
Intensity regulation can be carried out quickly and accurately by 
beam manipulation in the central region (i.e. in the first turns) of a 
cyclotron. However, this will need to be coupled with suitably fast 
monitoring and signalling at an appropriate location in the clinical 
beamline to ensure the beam delivered to the patient is also cut off 
suitably quickly. In addition to the time response of the signaling de-
tector, there is also the role played by the signal transfer time between 
the detection equipment at the steerer/interceptor within the cyclotron. 
The typical distances traversed by signals in a facility correspond to 
propagation delays of several hundred nanoseconds, which acts as an 
inherent lower limit on the beam interruption response time in the 
absence of predictive dose delivery, regardless of the detector type. 
Although this propagation delay corresponds to 10 4 of the total 100 ms 
dose delivery, it can contribute significantly to the dose error in those 
parts of the target volume when the beam shut-off is initiated. 
7. Synchrotrons 
Synchrotron-based systems for PBT are less common than cyclotron- 
based systems due to their increased complexity. The layout of the 
MedAustron synchrotron-based facility is shown in Fig. 5. They have 
the advantage that the extracted energy can be preselected by the ac-
celerator rather than requiring an external degrader. However, most 
present-day synchrotrons perform the dipole ramping at relatively slow 
rates; typically, a full dipole cycle — from injection energy up to ex-
traction and then back down again — takes a few seconds. Another 
limitation is that the majority of synchrotrons store only a single bunch 
Fig. 3. Layout of the PSI PROSCAN cyclotron-based proton therapy facility; taken from [20].  
Fig. 4. Example of typical transmission with energy through a cyclotron de-
grader and ESS: the Paul Scherrer Institute PROSCAN facility; figure reproduced 
from [60]. 
Fig. 5. Layout of the MedAustron accelerator and beamlines, including the four Irradiation Rooms (IR); adapted from [62].  
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of protons, which through space-charge limits and dipole cycle rate 
effectively limits the average dose rate that may be delivered to a pa-
tient treatment. A single injected bunch from a linear pre-accelerator is 
accelerated and then generally slowly extracted to deliver a stable dose 
rate to the patient. The beam current within a typical medical syn-
chrotron ring is shown in Fig. 6: note that the acceleration cycle takes 
less an a second but that the extraction of the beam takes nearly 10 s 
before the unwanted protons are dumped. 
In order to realise FLASH proton therapy with a synchrotron several 
technical challenges need to be overcome, some of which involve sig-
nificant design and operational changes. FLASH proton delivery will 
need to take advantage of multi-energy extraction: rather than dumping 
the remaining protons within the synchrotron ring after a single energy 
has been delivered, the remaining protons are re-accelerated or de-
celerated to match the next energy layer, thereby removing the need to 
re-inject fresh protons and accelerate from the low injection energy. 
This technique has been utilised for clinical treatment at HIMAC [63] 
and has been implemented and demonstrated with the Hitachi com-
mercial system [27]. However, this has been limited to a few energy 
layers, not an entire treatment, with energy adjustment between layers 
taking around 30 ms. To support this, a larger stored proton current 
within the synchrotron will also be necessary. 
7.1. High-current injection and storage 
Obtaining a high intensity requires a large bunch current; the pre-
sent maximum bunch charge in medical synchrotrons is 1012 protons: 
while this is above the ×4 1011 required for the 1 litre 40 Gy/s FLASH 
delivery (see Section 2), it doesn’t account for proton losses during 
beam extraction and delivery. This is largely a result of space charge 
limitations: increasing this will likely require a higher injection energy. 
This is not a technical limitation; linear accelerators exist in high-en-
ergy physics — such as Linac4 at CERN — that can accelerate orders of 
magnitude more protons to well above 100 MeV. This is a question of 
cost: increasing both the final energy and the transmitted current from 
the linac will result in a significant cost increase. 
7.2. Energy variation 
Assuming a large stored current is possible, a single dipole cycle 
could be utilised, meaning that multiple injection cycles are no longer 
necessary. However, in this case rapid multi-energy extraction is 
needed, covering the entire treatment volume rather than a subset of 
layers as is presently done. To meet the speed requirements for the full 
spot-scanning delivery of the 1 litre volume set out in Section 4, the 
synchrotron will need to adjust the beam energy and extract all the 
protons necessary for a given energy layer in 3 ms: this rises to 
6.25 ms when using the spot-reduced plan. This implies that the longest 
a synchrotron can take to go from a stable circulating beam at one 
energy to a stable circulating beam at another energy is 3 ms: this is 
at least an order of magnitude faster than is currently possible. As-
suming an energy step of 1.5 MeV (see Section 2) this implies an 
energy change 0.5 MeV/ms. Such a rate is not outside the capabilities 
of existing synchrotrons: Rapid Cycling Synchrotrons (RCSs), such as 
the ISIS spallation neutron source [64], are capable of accelerating at 
rates above 70 MeV/ms [49]. 
7.3. Rapid extraction 
Finally, assuming that it is possible to inject a suitable number of 
protons for the entire treatment into the synchrotron and adjust the 
energy for consecutive layers faster than 0.5 MeV/ms, stable extrac-
tion of all protons necessary for a single energy layer must be possible 
in <3 ms. The two most common methods for extraction from clinical 
synchrotrons are via RF knockout or betatron core extraction [65,66]. 
Both methods are intended to extract the beam slowly over the course 
of several seconds. RF knockout provides more stable extraction (albeit 
with variations that must be accounted for [67–69]) that can be swit-
ched on and off more quickly; systems utilising a betatron core need 
another device to deflect the beam downstream of the extraction point 
in order to switch the beam off between spots. 
To provide the temporal beam characteristics needed for FLASH 
spot scanning (see Section 4.1), the extraction time for a single energy 
layer will need to be reduced from several seconds to <3 ms, a reduction 
by 3 orders of magnitude. This clearly requires a novel approach not yet 
described. The large variations in current during extraction also need to 
be significantly reduced — ideally below 10% — in order to prevent 
under- or overdosing of individual spots. Ideally this new extraction 
method would have rise and fall times 600 ns to allow the beam to be 
switched off between spots when using the step-and-shoot method. This 
condition relaxes by a factor of two if using a continuous scan, but 
doing so places tighter constraints on the temporal stability since the 
beam cannot be switched on and off to deliver the correct dose for a 
given spot. 
The extracted pulse structure has a further implication for the RF 
frequency used for bunching and accelerating the beam. In present 
systems this is between 2–6 MHz, depending upon the size of the syn-
chrotron and the extraction energy. However, as described in Section  
4.1, the time to deliver a given spot is <600 ns for the clinical standard 
1 litre volume or <2.5 µs for the 125 ml volume. For the larger volume 
the number of protons extracted during a given turn must therefore be 
correct for a given spot, rather than being slowly accumulated; for the 
smaller volume far fewer turns would be available to accumulate the 
necessary dose compared to conventional proton therapy. In addition, 
the magnet switching time must be matched to the bunching frequency. 
An alternative would be to bunch and accelerate the beam at a much 
higher frequency — closer to 100 MHz, the frequency regime of cy-
clotrons — enabling protons extracted from several bunches to be de-
livered to a single spot. This has the disadvantage that the natural gap 
between bunches provided by the bunch structure within the ring 
Fig. 6. Beam current as a function of time during a typical acceleration cycle of the MedAustron synchrotron (courtesy of Claus Schmitzer, MedAustron). Vertical 
lines indicate the key stages in the acceleration and extraction cycle. 
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becomes much shorter, making it more difficult to use this for switching 
the beam off between spots. 
These extremely challenging requirements become relaxed some-
what when considering the hybrid systems described in Section 5. 
When using the broad beam option (see Section 5.1), the individual 
spot requirements are removed. The 10% stability requirement is also 
only necessary over one milliscond, rather having to be achieved in a 
microsecond. However, the need for multi-energy extraction is still 
present with its associated temporal requirements. For the scanned 
beam hybrid option (see Section 5.2), with a spot delivery time of 20 µs 
the interplay with the bunching frequency is no longer such an issue. In 
addition, multi-energy extraction is no longer required since only a 
single energy needs to be extracted from the synchrotron. The re-
quirements are still extremely challenging compared to existing sys-
tems, since the spill length can be no longer than 100 ms and the ex-
traction must be stable to 10% within the delivery time for each “spot” 
of 20 µs. Even more so than with cyclotrons, new technological ad-
vances will be required in order to realise FLASH delivery with syn-
chrotrons. Some possibilities may exist for synchrotrons with fast (ie. 
single turn) extraction in combination with a passive dose delivery 
system. 
8. Synchro-cyclotrons 
Most of the cyclotrons used in current PBT facilities are isochronous 
cyclotrons, which produce a effectively continuous current since their 
extraction pulse rate is typically 30–70 MHz (matching the constant RF 
at the accelerating Dees). Synchro-cyclotrons have also been introduced 
into modern proton therapy, and can offer a more compact footprint by 
using a higher average magnetic field above 4 T and even up to 9.4 T  
[70,71]. Synchro-cyclotrons utilise a varying Dee frequency which only 
a single accelerated bunch can be synchronous to, and are limited by 
the RF system to extracted bunch frequencies no more than about 
1 kHz; the intensity will therefore be limited by space charge and 
possible beam losses at extraction near superconducting coils. For ex-
ample, the IBA S2C2 5.7T synchro-cyclotron delivers a repetition rate of 
1 kHz with a maximum extracted current above 100 nA and a 7 µs long 
pulse [70]: the layout of the IBA S2C2-based Proteus One system is 
shown in Fig. 7. For the clinical specification given in Section 2, only 
100 pulses would be possible within the required 100 ms time window. 
This limits synchro-cyclotrons utilising step-and-shoot spot scanning to 
volumes around 1 cm3, assuming that the number of protons in a given 
pulse can be controlled accurately enough to give the correct dose to a 
single spot in a single pulse. 
Although possibilities may exist for synchro-cyclotrons in combi-
nation with a passive dose delivery system, for those delivery techni-
ques that require energy variation from the accelerator, such as spot 
scanning, this implies delivering one-third of each energy layer of a 
1 litre volume within in 7 µs unless there is a way to lengthen the pulse 
or increase the repetition rate. This makes a pure spot-scanning ap-
proach with a synchro-cyclotron more difficult than for an isochronous 
cyclotron. For the 125 ml and spot reduction plans outlined in Section 4 
— with half the number of energy layers — one-sixth of each layer will 
need to be covered within each 7 µs pulse. Since this implies covering 
several spots with a single pulse, continuous scanning will be necessary. 
A faster repetition rate would relax these constraints, but technical 
limitations inherent in the synchro-cyclotron design rule out repetition 
rates much above the 1 kHz used in existing systems. 
Initial experiments have been publicised in which small 
( × ×2 2 2 cm3) volumes have received FLASH dose rates in excess of 
60 Gy/s using scanned-beam delivery from a clinical synchro-cyclotron  
[73]. Extending this to larger treatment volumes will require either 
increased extracted current — which appears to be feasible up to per-
haps 150 Gy/s — or to deliver FLASH doses separately to different parts 
of a treatment volume, in other words not treat the whole volume at the 
same time. 
The hybrid systems presented in Section 5 provide alternative routes 
to clinical delivery, although challenges remain. The broad beam option 
may be more feasible if enough current can be delivered in each pulse 
to fully cover each layer in 3 pulses. For the scanned beam option, the 
scanning speed is more challenging for the 1 litre volume since, rather 
than being able to make a continuous or step-and-shoot scan within the 
required 100 ms time window, the pulsed synchro-cyclotron beam must 
cover 1% of the target volume within 7 µs. For the clinical volume 
defined in Section 2, this means scanning 25 spots in 7 µs or 280 ns per 
spot: this is twice as fast as the requirement for a spot-scanning system 
utilising a continuous rather than a pulsed beam (see Section 4.1). This 
is not possible with current technology and makes it unlikely that 
synchro-cyclotrons would be the eventual technology of choice for a 
pure spot-scanning FLASH proton therapy system. Assuming that the 
100 ms delivery window cannot be relaxed in order to achieve FLASH 
effects, if utilising the hybrid scanning modality described in Section  
5.2 synchro-cyclotrons would still be limited to 100 spots, so arrays of 
×10 10 columns, or scanning areas of ×2 2 cm2, as in the IBA ex-
periments [73]. Controlling the number of protons within each pulse to 
match the required dose for each column within the required tolerance 
would also be a necessary technological development, something that is 
not presently implemented. 
9. Linear accelerators 
Assessing the feasibility of pure linear accelerator-based systems for 
delivering FLASH proton therapy is more difficult than the other ac-
celerator technologies already mentioned because there are no such 
clinical systems presently in operation. A notable development is the 
LIGHT system of AVO-ADAM, which utilises 3 GHz high-gradient ac-
celerating structures to obtain protons up to 230 MeV in 2 µs pulses at 
up to 200 Hz [29]: the intended layout for this system is shown in  
Fig. 7. The IBA Proteus One compact proton therapy machine, which includes the superconducting synchro-cyclotron S2C2; adapted from [72].  
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Fig. 8. These bunch timescales are therefore quite similar to those of 
synchro-cyclotrons. 
The advantages of linac-based systems are the higher peak current 
and smaller beam emittance, coupled with the ability to vary the de-
livered energy pulse by pulse; no degrader is required, dispensing at 
low proton energies with the requirement for large accelerated currents 
and significant degrader losses [74]. However, a 200 Hz repetition rate 
gives only 20 separate delivered energy layers within the 100 ms time 
window specified in Section 2: this makes a full linac-based spot- 
scanning FLASH system unfeasible without increases in repetition rate 
of several orders of magnitude to enable repetition rates above 1 MHz. 
A recent planning study by AVO examined delivering FLASH dose 
rates within 0.5 s to 1 cm3 volumes; mean dose rates up to 93 Gy/s 
were predicted for overall doses of 20 Gy [75]. Delivering such sub- 
second doses to larger volumes will likely limit linacs to a broad-beam 
hybrid approach (see Section 5.1). For the example spot-scanned hybrid 
setup described in Section 5.2, 2,500 spots would have to be delivered 
to a 1 litre volume in 100 ms, implying a repetition rate of 25 kHz: ion 
sources and linacs that function at such high rep rates do not currently 
exist. It would also require the number of protons within each pulse to 
be accurate to 10% with a dynamic range large enough to cover all 
energy layers: this is extremely challenging. 
As such, a linac-based FLASH proton therapy system is less attrac-
tive than those based on continuous beam delivery, such as cyclotrons. 
As mentioned in Section 7.1, where linacs hold an advantage is in peak 
current, where the space charge limitations of circulating beam accel-
erators are no longer a factor. As such, should the clinical evidence 
point towards dose rates well above the present minimum of 40 Gy/s 
but within a delivery window longer than 100 ms — for example, in the 
circumstance where smaller volumes can be delivered at FLASH rates 
within a larger treatment volume — pulsed beams with high peak 
current become more attractive. This would open the door to FLASH 
delivery with linacs and synchro-cyclotrons. 
10. Conclusions 
Developing accelerator technology to meet the requirements for 
FLASH proton delivery is challenging. Whilst experiments have already 
been carried out with protons at FLASH dose rates [11–13,58,73], these 
have been limited so far to small volumes. Significant development will 
be required to enable FLASH delivery beyond these limitations, parti-
cularly if the goal is to adapt existing spot-scanning systems for use at 
FLASH dose rates to clinically relevant volumes: as described in Section  
4, developments in magnet scanning speed and dosimetry will be ne-
cessary before such systems can be realised. The hybrid approaches 
already being pursued — particularly the use of scanned beams with 
patient-specific range modulators — are likely to pave the way to 
clinical proton FLASH delivery. Each accelerator type has its own 
challenges in order to meet this goal. 
Isochronous cyclotrons. Existing clinical systems offer beam cur-
rents up to 800 nA, with research systems in existence capable of pro-
ducing currents above 100 µA. The key challenge for cyclotrons is the 
development of lower loss degraders and energy selection or large ac-
ceptance beam delivery, thereby reducing the requirement on max-
imum extracted current. 
Synchrotrons. Whilst the developmental challenges for FLASH 
systems based on synchrotrons appear daunting, none preclude the 
development of synchrotrons for FLASH. Linacs that can deliver the 
necessary peak current and synchrotrons capable of accelerating that 
current are already in existence, albeit not in clinical systems. The area 
that will require the greatest adaptation is in matching the extracted 
beam characteristics to that necessary for FLASH: this will necessitate 
staged acceleration of the stored protons to multiple energies without 
the need for re-injection and extraction of the resulting beam with a 
stability and pulse structure necessary for clinical FLASH delivery. With 
suitable increases in stored current and spot-scanning speed, FLASH 
proton therapy may be possible using existing synchrotrons coupled to 
the hybrid technology described in Section 5.2. 
Synchro-cyclotrons. Although some of the first FLASH proton ac-
celerator experiments have been carried out with synchro-cyclotrons  
[73], hard technical limitations are likely to prevent their use in fully 
fledged spot-scanning FLASH systems. Primarily, the repetition fre-
quency and pulse structure of synchro-cyclotrons is much less well- 
matched to FLASH beam delivery requirements than the stable CW 
beams produced by isochronous cyclotrons. Should “localised FLASH” 
be possible, wherein small subvolumes are treated at FLASH rates 
without the entire volume needing to be treated within 100 ms, syn-
chro-cyclotron-based FLASH systems become more feasible. It is likely, 
however, that it will be necessary to utilise some form of hybrid scan-
ning. 
Linacs. Even more so than for synchro-cyclotrons, the feasibility of 
developing linac-based FLASH proton therapy systems is highly de-
pendent on the eventual clinical requirements necessary for realising 
the FLASH effect. At present, the repetition rate is simply too slow to 
enable delivery to anything but small volumes: at an existing repetition 
rate of 200 Hz, an increase in this rate by a factor of >500 would be 
necessary for spot-scanned FLASH delivery to a 1 litre volume, or of 
>100 to enable the hybrid delivery described in Section 5.2. Pulsed 
beams are strongly biased towards high instantaneous current with 
longer delivery times: should dose rates in excess of 40 Gy/s be ne-
cessary but without the limitation to deliver the entire dose in 100 ms, 
synchro-cyclotrons and linacs become more attractive. 
Amongst current technologies, the most direct route to a clinical 
FLASH proton system appears to be with an isochronous cyclotron 
Fig. 8. Illustration of the linac-based LIGHT accelerator from AVO-ADAM; taken from [29]. The 3 main sections of the accelerator are highlighted from left to right: 
RadioFrequency Quadrupole (RFQ), a Side-Coupled Drift-Tube Linac (SCDTL) and a Cell-Coupled Linac (CCL). 
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utilising a hybrid spot-scanned approach. Significant changes in the 
mode of operation or treatment using synchrotrons, synchro-cyclotrons 
and linacs will be needed in order to enable a fully-fledged FLASH 
system. However, to design optimal technology for a FLASH system, 
more knowledge is needed on the biological and clinical issues, most 
importantly in the areas of minimum dose rate and maximum delivery 
time. Only with sufficient knowledge of FLASH processes could one 
exploit a possible NTCP reduction to allow certain technical compro-
mises to relax the constraints on the accelerator technology. 
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